In summary, our study shows that LGALS2 could be used as a diagnostic and prognostic marker for breast cancer, and that it regulates the biological activity of T cells to participate in tumor immunotherapy and reduces the occurrence of clinical drug resistance in patients. This evidence concerns the gene LGALS2 and breast carcinoma.